BioArctic AB (BIOAb)

Currency in SEK
329.0000
+6.0000(+1.86%)
Closed·
BIOAb is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
318.6000332.0000
52 wk Range
154.4000347.6000
Key Statistics
Prev. Close
323
Open
323.4
Day's Range
318.6-332
52 wk Range
154.4-347.6
Volume
188.61K
Average Volume (3m)
188.03K
1-Year Change
62.3889%
Book Value / Share
22.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BIOAb Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
295.6000
Downside
-10.15%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

BioArctic AB News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

BioArctic AB Company Profile

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company’s therapeutic areas encompass neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

Employees
122
Market
Sweden

Compare BIOAb to Peers and Sector

Metrics to compare
BIOAb
Peers
Sector
Relationship
P/E Ratio
48.9x−13.0x−0.6x
PEG Ratio
0.09−0.240.00
Price/Book
24.8x8.4x2.6x
Price / LTM Sales
25.5x18.2x3.4x
Upside (Analyst Target)
−10.3%83.4%41.1%
Fair Value Upside
Unlock−10.2%5.3%Unlock

Analyst Ratings

3 Buy
0 Hold
1 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 295.6000
(-10.15% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.98 / -1.00
Revenue / Forecast
133.35M / 146.48M
EPS Revisions
Last 90 days

BIOAb Income Statement

People Also Watch

419.50
ZELA
+3.00%
30.72
VIMIAN
-0.71%
155.60
TEL2b
-0.32%
211.00
BONEX
-5.30%
16.40
TRUEb
-2.96%

FAQ

What Is the BioArctic (BIOAb) Stock Price Today?

The BioArctic stock price today is 329.0000

What Stock Exchange Does BioArctic Trade On?

BioArctic is listed and trades on the Stockholm Stock Exchange stock exchange.

What Is the Stock Symbol for BioArctic?

The stock symbol for BioArctic is "BIOAb."

What Is the BioArctic Market Cap?

As of today, BioArctic market cap is 48.85B.

What Is BioArctic's Earnings Per Share (TTM)?

The BioArctic EPS (TTM) is 11.25.

When Is the Next BioArctic Earnings Date?

BioArctic will release its next earnings report on Feb 18, 2026.

From a Technical Analysis Perspective, Is BIOAb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has BioArctic Stock Split?

BioArctic has split 0 times.

How Many Employees Does BioArctic Have?

BioArctic has 122 employees.

What is the current trading status of BioArctic (BIOAb)?

As of Jan 17, 2026, BioArctic (BIOAb) is trading at a price of 329.0000, with a previous close of 323.0000. The stock has fluctuated within a day range of 318.6000 to 332.0000, while its 52-week range spans from 154.4000 to 347.6000.

What Is BioArctic (BIOAb) Price Target According to Analysts?

The average 12-month price target for BioArctic is SEK295.6, with a high estimate of SEK339 and a low estimate of SEK230. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an -10.15% Downside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.